WARSAW, Ind., March 06, 2018 -- WishBone Medical. Inc. entered into a U.S. distribution agreement with Implanet to distribute the JAZZ implant system to treat spinal pathologies requiring vertebral fusion surgery in the Orthopedic Market.
The first procedure with WishBone Medical surgeons was completed in early 2018. “We are looking forward to expanding our Orthopedic spine products and the JAZZ system is our first product in this market,” said Nick Deeter, Chairman of the Board and CEO at WishBone Medical.
Mr. Deeter added, “WishBone Medical provides innovative implants and instruments in sterile packed, single use disposable kits and the JAZZ implant system is available in these single use kits.”
Ludovic Lastennet, CEO of Implanet said, “This disruptive single use, sterile packed business model of WishBone Medical compliments the Implanet America JAZZ platform of single use, sterile packed products.”
To learn more about WishBone Medical, visit www.WishBoneMedical.com
About WishBone Medical, Inc.
WishBone Medical is a Global pediatric orthopedic company, committed to providing anatomically appropriate innovative implants and instruments in sterile packed, single use, disposable kits, to prevent infection, reduce overall costs for our customers and achieve the best outcomes for children around the world who are still growing.
For further information, visit www.WishBoneMedical.com or call Andrew Miclot, Vice-Chairman and President at 574-306-4006.
About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ® latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 staff and recorded 2017 sales of €7.8 million. For further information, please visit www.implanet.com.
Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Euronext™ Growth market in Paris. ALIMP
To learn more about IMPLANET, visit www.Implanet.com
Please contact WishBone Medical at 574-306-4006 or email [email protected] for more information. To learn more about WishBone Medical, visit www.WishBoneMedical.com.
Andrew J. Miclot
Vice Chairman & President
WishBone Medical, Inc.
2150 North Pointe Dr.
Warsaw, IN 46582
(574)306-4006 – Office
(574)527-0964 - Mobile
[email protected]


Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
DeepSeek to Raise AI API Prices as Demand for New Models Surges
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
OpenAI Restricts Astra AI Over Cyberattack Risks
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 



